Eli Lilly and Co (BSP:LILY34) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:LILY34 Eli Lilly and Co BSP:LILY34
94 GF Score
Price R$197.53
GF Value R$263.36
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co  (BSP:LILY34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.15 1.22 1.53 2.18 2.16

Eli Lilly and Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 1.55 2.17 1.62 1.99

BSP:LILY34 vs JNJ, ABBV, MRK: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.


BSP:LILY34
94GF Score
Eli Lilly and Co BSP:LILY34
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=64.951/333.9520*333.9520
=64.951

Current CPI (Jun. 2026) = 333.9520.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 7.941 241.428 10.984
201612 8.629 241.432 11.936
201703 7.779 243.801 10.655
201706 8.853 244.955 12.069
201709 8.486 246.819 11.482
201712 9.094 246.524 12.319
201803 7.675 249.554 10.271
201806 9.768 251.989 12.945
201809 10.206 252.439 13.502
201812 10.153 251.233 13.496
201903 9.749 254.202 12.808
201906 11.950 256.143 15.580
201909 11.832 256.759 15.389
201912 13.758 256.974 17.879
202003 14.347 258.115 18.562
202006 16.226 257.797 21.019
202009 16.939 260.280 21.734
202012 22.008 260.474 28.216
202103 20.435 264.877 25.764
202106 19.626 271.696 24.123
202109 19.434 274.310 23.659
202112 24.568 278.802 29.428
202203 22.517 287.504 26.155
202206 17.685 296.311 19.932
202209 20.144 296.808 22.665
202212 20.204 296.797 22.733
202303 20.003 301.836 22.131
202306 22.814 305.109 24.971
202309 25.765 307.789 27.955
202312 24.417 306.746 26.583
202403 24.018 312.332 25.681
202406 32.562 314.175 34.612
202409 35.048 315.301 37.121
202412 41.688 315.605 44.111
202503 41.325 319.799 43.154
202506 49.000 322.561 50.730
202509 53.350 324.800 54.853
202512 55.080 324.054 56.762
202603 58.081 330.213 58.739
202606 64.951 333.952 64.951

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Eli Lilly and Co (BSP:LILY34) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of R$197.53 is trading 25% below its estimated GF Value™ of R$263.36. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for BSP:LILY34:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: R$263.36 vs. price of R$197.53 (25% below fair value)
  • GF Score™: 94/100 with 2 warning signs

No single metric tells the full story. See the BSP:LILY34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
94GF Score

Get the complete analysis for BSP:LILY34

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$197.53
Price
R$263.36
GF Value